BPC-157 Pricing: September 2026
BPC-157 runs $39-$55 per research vial, $75-$150 per compounded 5 mg vial, and $199-$350/mo via telehealth. HHS eased enforcement on Oct. 28.
Update (October 29, 2026): HHS will not act against pharmacies that compound BPC-157 under its new policy. On October 28, HHS filed a notice saying it will not take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound BPC-157 or five other peptides, as long as they meet its conditions. The policy does not approve BPC-157 or add it to the 503A bulks list, and HHS can revisit it if safety or quality problems appear. Statements below about the FDA's next steps describe the situation in early September. No pharmacy had posted a price under the new policy by October 29, so the price rows are unchanged. Our explainer on the policy covers the details.
The price picture as of September 2, 2026. BPC-157 (Body Protection Compound-157) is a synthetic peptide copied from a protein in human stomach fluid, and no regulator has approved it for any human use. Prices have barely moved since our April guide. Research vendors sell a 5 mg vial for about $39 and a 10 mg vial for $48 to $55. A compounding pharmacy, which makes the drug to order for one patient's prescription, charges $75 to $150 for a 5 mg vial. Telehealth programs that bundle the visit, the drug, and shipping start near $199 a month and top out around $350. Insurance covers none of it.
What the July vote did and did not do. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8-6, with one abstention, to recommend BPC-157 for the Section 503A bulks list. That list names the raw ingredients a licensed pharmacy may use when it compounds a drug for a named patient, while Section 503B covers large outsourcing facilities that make batches without patient-specific prescriptions under a separate list. The vote is advice. The FDA still has to publish a proposed rule, take public comments, and issue a final rule before a pharmacy can legally compound BPC-157. Holland & Knight's August 4 legal note said these peptides "still cannot be lawfully compounded," and no proposed rule had appeared by the end of August. Our piece What the FDA panel's yes vote changed, and what it did not walks through the remaining steps.
Where clinics stand. The pharmacies and telehealth clinics in the tables below sold compounded BPC-157 before the vote and kept selling it afterward at the same prices, though some clinicians want no part of it. On June 25, 2026, UVA Health obesity medicine director Catherine Varney told WSET she will not prescribe BPC-157 or TB-500 because the evidence comes from animal studies. Abroad, Australia's Therapeutic Goods Administration made unapproved peptides a formal compliance priority in June 2026, with BPC-157 heading its list and import seizures and fines among the tools.
What's next. A second PCAC peptide meeting is due before the end of February 2027, covering five other peptides, GHK-Cu among them; BPC-157's vote is already done. For all six recommended peptides in one place, see Post-PCAC 503A peptide pricing 2026, and for the stack with TB-500, see TB-500 pricing. Research-vendor rows below are for market context only, since those products are labeled research use only and are not for human use.
HHS enforcement policy, October 28, 2026
On October 28, 2026, HHS said it will not take enforcement action against 503A pharmacies that compound BPC-157 and five other peptides under set conditions. BPC-157 is still not FDA-approved or on the bulks list, and no pharmacy had posted a price under the policy by October 29.
| Channel | Price | Source |
|---|---|---|
| HHS enforcement discretion notice | Filed Oct. 28, 2026 | Federal Register (public inspection) |
| What the policy does not do | No approval, no list change | Federal Register (public inspection) |
| Conditions for pharmacies | Single ingredient, tested source, Rx | American Med Spa Association |
| Multi-peptide blends | Outside the stated terms | American Med Spa Association |
| 503B outsourcing facilities | Not covered | NPR via KPBS |
| Compounded prices under the policy | Not yet published | NPR via KPBS |
After the July 2026 PCAC vote
Status of BPC-157 and the peptides it is usually stacked with, as of September 2, 2026. PCAC is an advisory panel whose votes recommend but do not change the law, so nothing in this table let a pharmacy compound BPC-157. HHS's October 28 policy, in the table above, is a separate step.
| Channel | Price | Source |
|---|---|---|
| BPC-157 (PCAC vote, July 23, 2026) | Recommended 8-6-1 | Medical Daily |
| TB-500 (PCAC vote, July 23, 2026) | Recommended 8-6 | Medical Daily |
| KPV (PCAC vote, July 23, 2026) | Recommended 8-6-1 | Medical Daily |
| GHK-Cu | Not on the July agenda | FDA |
| Legal effect of the vote | Advisory only | STAT News |
| FDA rulemaking status | No proposed rule as of August 2026 | Holland & Knight |
| Next PCAC peptide meeting | Before end of February 2027 | FDA |
Telehealth and peptide clinics (prescription plus medication)
Bundled programs that include the consultation, the prescription, the compounded drug, and shipping, which is the most common way patients get BPC-157 with a clinician involved. Prices below match what each page showed on September 2, 2026.
| Channel | Price | Source |
|---|---|---|
| Maximus (telehealth) | ~$199/mo | ClinicLayer |
| Defy Medical (telehealth) | $200–$250/mo | ClinicLayer |
| Med-spa and convenience clinics | $150–$350/mo | PeakedLabs |
| Florida Bariatric & Plastic Surgery MD (Palm Beach County) | $350/mo | Florida Bariatric & Plastic Surgery MD |
| Specialist peptide clinics | $200–$500/mo | PeakedLabs |
| BeyondMD (BPC-157/KPV/TB-500 injectable) | From $199/mo | BeyondMD |
Compounding pharmacies (prescription required)
A 503A pharmacy makes BPC-157 to a prescription for one patient, which is the pathway the PCAC vote addressed. The FDA has not changed the list, but since October 28 HHS says it will not take enforcement action against pharmacies that meet its conditions. These are guide ranges rather than one pharmacy's price list, since pharmacies quote by vial size and concentration.
| Channel | Price | Source |
|---|---|---|
| Compounded 5 mg vial | $75–$150/vial | Pure Peptide Clinic |
| Compounded 10 mg vial | $120–$200/vial | Pure Peptide Clinic |
| Compounded oral capsules (30-day supply) | $90–$180 | Pure Peptide Clinic |
| Full program (medication plus monitoring) | $200–$600/mo | Pure Peptide Clinic |
| RealPeptides 'compounding pharmacy' tier (5 mg) | $90–$140/vial | RealPeptides |
Oral capsules and sprays
Oral BPC-157 absorbs less than an injection, which is why capsule doses run higher. Two kinds of product appear here: telehealth capsules that need a prescription, and research-labeled capsules sold without one. Integrative Peptides, listed in April, now hides prices behind a professional login, so it is gone from this table.
| Channel | Price | Source |
|---|---|---|
| BeyondMD (BPC-157/TB-500 capsules, Rx) | From $249/mo | BeyondMD |
| Team Wellcore (BPC-157/TB-500 capsules, Rx) | $274/mo | Team Wellcore |
| SwissChems (BPC-157 capsules, research use only) | $85.95/60 capsules | SwissChems |
Research peptide vendors (research use only)
Sold for laboratory research, not for human use, and included for market context only; prices are per vial of freeze-dried powder that must be mixed with bacteriostatic water. Limitless Life Nootropics, listed in April, now shows prices only to logged-in professional accounts, so it was dropped.
| Channel | Price | Source |
|---|---|---|
| Bluum Peptides (5 mg) | $39/vial | Bluum Peptides |
| Ion Peptides (10 mg) | $48/vial | Peptide Grades |
| Verified Peptides (10 mg) | $53/vial | Peptide Grades |
| Alpha Omega Peptide (10 mg) | $55/vial | Alpha Omega Peptide |
| SwissChems (BPC-157 + TB-500 blend) | $119.95/vial | SwissChems |
| Market range (5 mg research vial) | $38–$95/vial | RealPeptides |